share_log

Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target

Moomoo 24/7 ·  Apr 10 09:35

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment